Can Zyprexa (olanzapine) be combined with mirtazapine, and what are the recommended dosing and monitoring guidelines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Zyprexa (Olanzapine) and Mirtazapine Be Combined?

Yes, olanzapine and mirtazapine can be safely combined, with no clinically significant pharmacokinetic interactions between these medications. 1

Evidence for Safety of Combination

The combination has been studied specifically and demonstrates:

  • No pharmacokinetic interaction: A prospective study in 24 patients with chronic schizophrenia found that adding mirtazapine 30 mg/day to olanzapine 10-20 mg/day resulted in only minimal, statistically insignificant changes in olanzapine plasma concentrations 1
  • Good tolerability: The combination was well-tolerated with no serious adverse events reported 1
  • Clinical utility: Both medications are recognized as sedating agents that may be used together in specific clinical contexts 2

Clinical Applications Where This Combination May Be Appropriate

Insomnia with Comorbid Conditions

The combination appears in insomnia treatment algorithms as:

  • Mirtazapine is listed among sedating antidepressants (15-30 mg at bedtime) for treating insomnia, especially with comorbid depression/anxiety 2, 3
  • Olanzapine (quetiapine and olanzapine specifically) is listed as "other sedating agents" suitable for patients with comorbid insomnia who may benefit from the primary action of these drugs 2
  • The guideline sequence suggests trying sedating antidepressants before atypical antipsychotics, or combining them if monotherapy fails 2

Psychiatric Conditions

  • Schizophrenia with residual negative symptoms: The combination showed slight improvement in negative symptoms when mirtazapine was added to olanzapine 1
  • Anorexia nervosa with major depression: One case report demonstrated successful treatment with olanzapine 10 mg/day plus mirtazapine 30 mg/day, resulting in weight restoration and depression remission 4

Cancer-Related Symptoms

Recent evidence suggests both medications are effective for:

  • Psychological distress: Both reduce anxiety and depression in oral cancer patients, with mirtazapine showing slightly greater efficacy 5
  • Cachexia-anorexia: Mirtazapine demonstrated stronger appetite stimulation effects than olanzapine 6

Dosing Recommendations

Starting doses when combining:

  • Olanzapine: 2.5-5 mg at bedtime 7, 3
  • Mirtazapine: 7.5-15 mg at bedtime 3, 2

Titration:

  • Olanzapine: Can increase to maximum 10 mg/day in divided doses 3
  • Mirtazapine: Can increase to 30 mg at bedtime 3

Critical Safety Warnings

Avoid Combining with Benzodiazepines

Caution: Fatalities have been reported with concurrent use of benzodiazepines with high-dose olanzapine 7. The combination of olanzapine with benzodiazepines carries risk of:

  • Oversedation
  • Respiratory depression
  • Increased mortality risk

If benzodiazepines must be used with this combination, use the lowest possible doses (e.g., lorazepam 0.25-0.5 mg) 7.

Monitoring Requirements

Essential monitoring includes:

  • Metabolic effects: Both medications cause weight gain and metabolic changes 7, 3, 8
    • Monitor weight, fasting glucose, lipid panel
    • Consider prophylactic metformin with olanzapine to attenuate weight gain 8, 9
  • Sedation: Additive sedation is expected; warn about driving and operating machinery
  • Orthostatic hypotension: Both can cause this, particularly in elderly patients 7, 3
  • Anticholinergic effects: Mirtazapine has some anticholinergic properties 3

Special Populations

Elderly patients:

  • Reduce olanzapine dose (start 2.5 mg) 7, 3
  • Reduce mirtazapine dose (start 7.5 mg) 3
  • Higher risk of falls, confusion, and metabolic effects

Hepatic impairment:

  • Reduce doses of both medications 7

Practical Algorithm for Use

  1. Determine primary indication: Is this for insomnia, psychiatric symptoms, or cancer-related symptoms?

  2. Start low: Begin with olanzapine 2.5 mg and mirtazapine 7.5 mg, both at bedtime

  3. Titrate based on response:

    • If inadequate response after 5-7 days, increase mirtazapine to 15 mg
    • If still inadequate after another week, increase olanzapine to 5 mg
    • Maximum effective doses: olanzapine 10 mg, mirtazapine 30 mg
  4. Monitor closely:

    • Assess sedation, orthostasis, and metabolic parameters at 2-4 weeks
    • Check weight, glucose, lipids at baseline and 3 months
  5. Reassess need after 9 months: Attempt dose reduction to determine if continued treatment is necessary 3

Common Pitfalls to Avoid

  • Do not combine with benzodiazepines unless absolutely necessary and at minimal doses
  • Do not ignore metabolic monitoring: Weight gain and metabolic syndrome are significant risks with both medications
  • Do not use in elderly patients with dementia-related psychosis: Olanzapine carries a black box warning for increased mortality in this population 10
  • Do not assume drug interactions: While these two medications don't interact with each other, both can interact with other medications through CYP450 pathways

References

Guideline

clinical guideline for the evaluation and management of chronic insomnia in adults.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

Research

Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression.

Progress in neuro-psychopharmacology & biological psychiatry, 2006

Guideline

american association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.